Results 11 to 20 of about 87,925 (315)

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

American Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023
Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb, Gaurav Sutrave, Wei Jiang, Selmir Avdic, Janine A. Street, Renee Simms, Leighton E. Clancy, Vicki Antonenas, Brian S. Gloss, Caroline Bateman, David C. Bishop, Kenneth P. Micklethwaite, Emily Blyth   +12 more
wiley   +1 more source

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

American Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Péter Reményi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kröger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha, on behalf of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +25 more
wiley   +1 more source

Molecular and cellular paradigms of multidrug resistance in cancer

Cancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya, Abu Sufiyan Chhipa, Vinita Mishra, Vishal Kumar Gupta, Shiv Govind Rawat, Ajay Kumar, Chandramani Pathak   +6 more
wiley   +1 more source

Molecular testing of soft tissue tumors

Diagnostic Cytopathology, Volume 51, Issue 1, Page 12-25, January 2023., 2023
Abstract Background The diagnosis of soft tissue tumors is challenging, especially when the evaluable material procured is limited. As a result, diagnostic ancillary testing is frequently needed. Moreover, there is a trend in soft tissue pathology toward increasing use of molecular results for tumor classification and prognostication. Hence, diagnosing
Douglas Rottmann, Eman Abdulfatah, Liron Pantanowitz   +2 more
wiley   +1 more source

Analysis of drug interactions with serum proteins and related binding agents by affinity capillary electrophoresis: A review

ELECTROPHORESIS, Volume 43, Issue 23-24, Page 2302-2323, December 2022., 2022
Abstract Biomolecules such as serum proteins can interact with drugs in the body and influence their pharmaceutical effects. Specific and precise methods that analyze these interactions are critical for drug development or monitoring and for diagnostic purposes.
Sadia Sharmeen, Isaac Kyei, Arden Hatch, David S. Hage   +3 more
wiley   +1 more source

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. [PDF]

PLoS Pathogens, 2015
Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors.
Ruth J Napier, Brian A Norris, Alyson Swimm, Cynthia R Giver, Wayne A C Harris, Julie Laval, Brooke A Napier, Gopi Patel, Ryan Crump, Zhenghong Peng, William Bornmann, Bali Pulendran, R Mark Buller, David S Weiss, Rabindra Tirouvanziam, Edmund K Waller, Daniel Kalman   +16 more
doaj   +1 more source

Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI

Hematological Oncology, Volume 40, Issue 5, Page 1041-1055, December 2022., 2022
Abstract The medium‐dose etoposide (VP16) added on cyclophosphamide (CY)/total body irradiation (TBI) is one of the intensified myeloablative conditioning regimens used in allogenic hematopoietic stem cell transplantation (allo‐HSCT) for acute lymphoblastic leukemia (ALL).
Mari Morita‐Fujita, Yasuyuki Arai, Tadakazu Kondo, Kaito Harada, Naoyuki Uchida, Takashi Toya, Yukiyasu Ozawa, Takahiro Fukuda, Shuichi Ota, Makoto Onizuka, Yoshinobu Kanda, Yumiko Maruyama, Satoru Takada, Toshiro Kawakita, Takahide Ara, Tatsuo Ichinohe, Takafumi Kimura, Yoshiko Atsuta, Shinichi Kako   +18 more
wiley   +1 more source

Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation. [PDF]

PLoS ONE, 2013
Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite whether imatinib is required to maintain CMR.
Hua Jin, Yiying Xiong, Jing Sun, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Dan Xu, Yongqiang Wei, Min Dai, Ru Feng, Qifa Liu   +11 more
doaj   +1 more source

SRCircumventing imatinib resistance [PDF]

Cancer Cell, 2004
The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses.
Brian J. Druker, Brian J. Druker, Michael W. Deininger   +2 more
openaire   +2 more sources

A conservative treatment for eosinophilic cystitis

IJU Case Reports, Volume 6, Issue 1, Page 8-12, January 2023., 2023
Introduction Eosinophilic cystitis is a rare condition which causes common symptoms and may mimic other conditions. Eosinophilic cystitis has several causes such as hypereosinophilic syndrome, inflammatory diseases, neoplasia, parasites or fungal infection, IgE‐related diseases, Drug Reaction and Eosinophilia and Systemic Symptoms (DRESS) syndrome, or ...
Franco Alchiede Simonato, Nicola Pavan, Mirko Pinelli, Gabriele Tulone, Rosa Giaimo, Anna Martorana, Alchiede Simonato   +6 more
wiley   +1 more source